



Full-Year Results 2023

Investor and Media Conference

February 16, 2024

Delivering Growth – in Asia and Beyond.

Agenda



- 1. Highlights FY 2023
- 2. Business Units Review
- 3. Financial Update
- 4. Outlook





Highlights FY 2023

FY 2023 Results Underline Continued Value Creation



DKSH Value Creation			FY 2023 Realization		FY 2019 - 2023
					CAGR ⁴
	Growth	Achieve above GDP ¹ net sales growth		Net Sales: +5.3% at CER ²	+3.3%
7	Profitability	Expand margin		Core EBIT: +12.6% at CER ² Margin 3.0% (+15 bps)	+10.1% (+60 bps)
	Cash Efficiency	Drive cash conversion		Free Cash Flow: CHF 282.3 million Cash Conversion: 137.0%	+15.9%
*	Capital Allocation	Increase dividend and targeted M&A based on strong balance sheet		Ordinary Dividend: 11 th consecutive increase to CHF 2.25 per share ³	+4.3%


DKSH maintains track record of growth, margin expansion, and strong cash conversion

¹ Weighted GDP calculation based on DKSH 2023 Net sales market split. ² Constant exchange rates (CER): Figures converted at 2022 exchange rates. ³ Proposal by the Board of Directors. ⁴ Constant exchange rates (CER): Figures converted at 2019 exchange rates. ^{*} For the definition of Alternative Performance Measures (APM), see Annual Report 2023

>


DKSH Is Moving Forward Value Driving Programs





Fulfilling its purpose of enriching people's lives

More Than 80% of M&A Spend on Higher Profitability Business 🍣 DKSH




Restoring the M&A pace in H2 2023 and entering 2024 with a strong balance sheet

¹ Healthcare Own Brands is a part of Business Unit Healthcare; ² Core EBIT Margin ³ M&A spend percentage in rounded values

Continuation of Progressive Dividend Policy



Ordinary dividend per share (in CHF)



DKSH proposes an increase of the ordinary dividend by 4.7% to CHF 2.25 per share²

>




Business Units Review








Expand strong market position and drive into higher value segments and services






- Accelerated Net sales growth driven by solid business development and strong underlying market
 - Expansion with existing and new clients in Thailand, Malaysia, Vietnam, etc.
- Focus on growing higher added-value segments and services
 - Expansion of Own Brands business and Medical Devices, as well as fullagency services
 - Continued M&A focus:
 - o Partizan in Australia
 - Medipharm in Brunei (in 2024)
- Core EBIT margin further increased after strong FY 2022 from 2.6% to 2.8%

¹ Constant exchange rates (CER)

* For the definition of Alternative Performance Measures (APM), see Annual Report 2023







Core EBIT (in CHF million)



- Net sales growth of 2.2% due to client wins and expansion despite lower consumer sentiment and subdued market volumes
- Strengthened beauty care segment with CS&Co. acquisition
- Core EBIT at +2.2% (CER) above previous year at robust margin
- Strategic direction has evolved to an even stronger focus on its FMCG business
 - FMCG business is growing ahead of CG total and accounts for ~95% of BU Consumer Goods with a slightly higher margin
- Fully exited non-profitable, non-core fashion retail business

¹ Constant exchange rates (CER)


For the definition of Alternative Performance Measures (APM), see Annual Report 2023



Business Unit Performance Materials



Strengthen leading position in specialty chemicals and ingredients distribution



- Sales growth of 6.1% at CER is driven by contributions from M&As and our Life Sciences portfolio
- Life Sciences portfolio growing in Asia Pacific and Europe at CER
- Strong gross margin increase with disciplined pricing management and strong cost control incl. rightsizing
- Core EBITA at +17.4% (CER), strongly above previous year
- Core EBITA Margin increase by 80 bps with positive contributions by all regions
- Successfully reduced inventory levels and improved working capital

¹ Constant exchange rates (CER)

^{*} For the definition of Alternative Performance Measures (APM), see Annual Report 2023









Core EBIT (in CHF million)



- Double-digit Net sales and Core EBIT growth (in CER)
- Diligently executed strategy and continued to grow key areas
 - Scientific Instrumentation, Precision Machinery, Semiconductor Industry
 - Consumables and Service business
 - M&A: acquisition of Bio-Strategy in Australia and New Zealand
- Further market consolidation potential ahead
- Business Unit will keep fostering its position in key industries and higher margin segments and services

¹ Constant exchange rates (CER)

* For the definition of Alternative Performance Measures (APM), see Annual Report 2023






Financial Update

FY 2023 – Continued Good Financial Performance





DKSH maintains track record of growth, margin expansion, and strong cash conversion

¹ Constant exchange rates (CER): 2023 figures converted at 2022 exchange rates ^{*} For the definition of Alternative Performance Measures (APM), see Annual Report 2023


>

Strong Core EBIT Growth

Net Sales (in CHF million)




Core EBIT (in CHF million)



¹ Constant exchange rates; ² Including share of result in associates (CHF 7.5 million), discontinuation of fashion retail business (CHF 11.7 million), goodwill impairment (CHF 3.9 million) and fair value adjustment related to employee benefit expenses (CHF 0.9 million). * For the definition of Alternative Performance Measures (APM), see Annual Report 2023

Strong Long-Term Performance





DKSH maintains track record of growth, margin expansion, and strong cash conversion

¹ Constant exchange rates (CER): Figures converted at 2019 exchange rates.

* For the definition of Alternative Performance Measures (APM), see Annual Report 2023

Continued Strong Balance Sheet With Significant Leverage Potential

in CHF million	FY 2022	FY 2023	
Cash and cash equivalents	636.4	687.2	
Trade receivables	2,030.9	1,840.7	
Inventories	1,277.3	1,138.0	
Intangibles	825.4	785.6	
Right-of-use assets	317.4	261.5	
Other assets	791.3	758.2	
Trade payables	2,233.2	2,025.3	
Borrowings	678.7	680.7	
Lease liabilities	333.9	277.5	
Other liabilities	806.6	749.8	
Total equity	1,826.3	1,737.9	
Total equity and liabilities	5,878.7	5,471.2	

DKSH

Continued strong financial metrics:

- Strong liquidity position maintained and even improved
- Continued strong working capital management
 - Receivables management drive lean working capital balance
 - Managed to reduce inventory levels
 - Balanced trade payables and receivables management
- Solid equity ratio of 31.8%
- Significant leverage headroom (net cash surplus)

Additional Financial Indications



	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024 Estimate	Mid-Term Estimate
M&A (net sales contribution)	2.1%	0.8%	1.5%	2.1%	0.5% to 1.5% ¹	Further M&A ambitions
FX (net sales contribution)	(5.1%)	(2.0%)	(2.6%)	(7.5%)	(3% to 5%) ²	n.a.
Tax rate (% of profit before tax)	26.1%	27.8% ³	27.1%	28.1%	27% to 29%	27% to 29%
Capex (% of net sales)	0.4%	0.5%	0.4%	0.3%	0.5%	0.5%

¹ Based on acquisitions signed and closed until publication of Annual Report 2023 results

² If current spot rates prevail for the remainder of the year

³ Excludes gain on sale to aCommerce (CHF 10.3 million) and share of loss in associate (CHF -9.1 million) as well as revaluation gain of aCommerce (CHF 34.8 million)



Outlook

Current Macroeconomic Landscape

- Asia Pacific continues to be a key driver of global growth
- Increasing population and growing trade activities
- Growing tourism trends supportive for economic development in Asia Pacific
- Inflation has returned to pre-pandemic levels as supply-side pressures have eased and monetary tightening has taken effect


Prospects For 2024 and Beyond

- DKSH committed to deliver GDP+¹ sales growth² (at CER) in fast-growing Asian markets
- Core EBIT growth (at CER) in 2024 expected²
- Further M&A consolidation potential



Capital Markets Day

H2 2024 - London



¹ Weighted GDP calculation based on DKSH 2023 Net sales market split. ² Outlook assumes economic growth in Asia Pacific, stable exchange rates, and barring unforeseen events.




Appendix

(me


Ste DKSH

EBIT to Core EBITA Bridge





Core EBITA 2022 (in CHF million)



Disclaimer



While this presentation has been prepared by DKSH with due care and based on information it reasonably believes to be accurate, complete and up-to-date on the date hereof, this presentation may be inaccurate or incomplete or contain typographical errors or information that is not up-to-date. DKSH does not assume any liability for relevance, accuracy or completeness of the information included in this presentation. DKSH reserves the right to change, supplement or delete at any time some or all of the information included in this presentation without notice.

This presentation may contain certain forward-looking statements relating to DKSH and its business, including, but not limited to, statements regarding DKSH's financial position, business strategy, plans and objectives of management for future operations. Words like "believe", "anticipate", "expect", "project", "estimate", "predict", "intend", "target", "assume", "may", "might", "could", "should", "will" and similar expressions may indicate such forward-looking statements. Forward-looking statements are based on numerous assumptions regarding, among other things, DKSH's present and future business strategies and the environment in which DKSH will operate in the future, some of which are beyond DKSH's control. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of DKSH to be materially different from those expressed or implied by such statements. Readers of this presentation should therefore not place undue reliance on these statements. In particular, readers should not rely on any forward-looking statements in this presentation in connection with their entering into any contract or forming an investment decision. DKSH disclaims any obligation to update any forward-looking statements.

The layout, graphics and other contents of this presentation are protected by copyright law and may not be reproduced or used without DKSH's prior written consent.